Cytokinetics, Incorporated · NASDAQ:CYTK

Callos Andrew sold 11,333 Cytokinetics, Incorporated shares (Form 4)

Traded May 5, 2026 · Filed May 5, 2026

On May 5, 2026, Callos Andrew (EVP, Chief Commercial Officer) sold 11,333 Cytokinetics, Incorporated shares at US$77.25 for US$875K under a trading plan, leaving 58,555 shares. Filed May 5, 2026 (Form 4).

Sold
11,333 shares
Price
US$77.25
Value
US$875K
Holding after
58,555 shares
Trading plan
Yes (Made under a plan set in advance)
Role
EVP, Chief Commercial Officer

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
May 5, 2026Common StockOption exercise11,333US$39.1369,888Direct
May 5, 2026Common StockSale11,333US$77.2558,555Direct

Source

View original at SEC

Related